News

Trials of early-stage study on coronavirus vaccine show promise

The single-blind, randomised, controlled trial found that neutralising antibody responses were reported in 91% of 35 patients when utilising one test and 100% of 35 patients when using a different test

Shares of AstraZeneca, 0.93% were down 3.4% in trading on 20 July after a medical journal published a study that found the company’s Covid-19 vaccine candidate produced antibody and T-cell responses in participants in a Phase 1/2 clinical trial.

AstraZeneca is developing the experimental vaccine with the University of Oxford; the study was published in The Lancet.

WSJ Logo
How Trump Got His ‘Big, Beautiful Bill’ Across the Finish LineExternal link

How Trump Got His ‘Big, Beautiful Bill’ Across the Finish Line